SITC Cancer Immunotherapy Guideline – Acute Leukemia

SITC Cancer Immunotherapy Guidelines (CIGs) are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies, among other topics.

The SITC consensus statement on immunotherapy for the treatment of acute leukemia was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. Containing consensus recommendations regarding FDA-approved immunotherapies for acute lymphoblastic and acute myeloid leukemia, as well as discussion of promising emerging treatment modalities, the clinical practice guideline will provide a valuable resource for the oncology community.

SITC Acute Leukemia Immunotherapy Guideline Expert Panel

Members

Ivan Aksentijevich, MD  — Virginia Cancer Specialists

Daniel A. Arber, MD — University of Chicago

John Barrett, MD — National Institutes of Heath

Renier J. Brentjens, MD, PhD — Memorial Sloan-Kettering Cancer Center

Jill Brufsky, PharmD — Patient Advocate

Jorge Cortes, MD — The University of Texas MD Anderson Cancer Center

Marcos De Lima, MD — Case Western Reserve University

Stephen J. Forman, MD — City of Hope

Ephraim J. Fuchs, MD — Johns Hopkins

Linda J. Fukas — Nursing Professional

Steven D. Gore, MD — Yale University

Mark R. Litzow, MD — Mayo Clinic Cancer Center

Jeremy S. Miller, MD — University of Minnesota

John M. Pagel, MD, PhD — Swedish Cancer Institute

Edmund K. Waller, MD, PhD, FACP — Emory University